Skip to main content

Periodontal Diseases

1
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Lynch Biologics
Lynch BiologicsTN - Franklin
1 program
1
Allograft and rHPDGF-BBPhase 21 trial
Active Trials
NCT06162832Unknown30Est. Jan 2025
Geistlich Pharma
Geistlich PharmaSwitzerland - Root
2 programs
Connective Tissue Graft TechniqueN/A1 trial
Periodontal Access FlapN/A1 trial
Active Trials
NCT04356391Completed43Est. Apr 2023
NCT06309719Recruiting24Est. Dec 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
BioXclude™N/A1 trial
Active Trials
NCT03836378Active Not Recruiting250Est. Nov 2027
Biolase
BiolaseCA - Foothill Ranch
1 program
MISTN/A1 trial
Active Trials
NCT04169139Completed54Est. May 2020
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
PeriActivePHASE_41 trial
Active Trials
NCT02987634Unknown44Est. Feb 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Jerusalem PharmaceuticalsPeriActive
Lynch BiologicsAllograft and rHPDGF-BB
Geistlich PharmaPeriodontal Access Flap
Colorado TherapeuticsBioXclude™
BiolaseMIST
Geistlich PharmaConnective Tissue Graft Technique

Clinical Trials (6)

Total enrollment: 445 patients across 6 trials

NCT02987634Jerusalem PharmaceuticalsPeriActive

Evaluation and Comparison of Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Mouth Rinse

Start: Dec 2018Est. completion: Feb 202044 patients
Phase 4Unknown
NCT06162832Lynch BiologicsAllograft and rHPDGF-BB

Periodontal Regeneration With Recombinant Human Platelet Derived Growth Factor (rH-PDGF-BB) and Allograft

Start: Jan 2024Est. completion: Jan 202530 patients
Phase 2Unknown
NCT06309719Geistlich PharmaPeriodontal Access Flap

Hyaluronic Acid and Polynucleotides for Supra-bony Defects

Start: Oct 2024Est. completion: Dec 202624 patients
N/ARecruiting
NCT03836378Colorado TherapeuticsBioXclude™

Addition of Dehydrated Human Amnion-Chorion Membrane During Scaling and Root Planing

Start: Nov 2020Est. completion: Nov 2027250 patients
N/AActive Not Recruiting
NCT04169139BiolaseMIST

Controlled Study Comparing REPaiR® and MIST Therapies for Treatment of Periodontitis

Start: May 2018Est. completion: May 202054 patients
N/ACompleted
NCT04356391Geistlich PharmaConnective Tissue Graft Technique

Pinhole Surgical Technique Compared to Connective Tissue Graft in Treatment of Gingival Recession

Start: Jan 2018Est. completion: Apr 202343 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 445 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.